Dosimetry of Intralesional 131I-Monoclonal Antibody (MAb) Therapy in Patients with Recurrent High Grade Gliomas

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-0348-7340-6_5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I‐labelled anti‐tenascin monoclonal antibody BC‐2

  1992cited by this paper
• Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

  1989cited by this paper
• Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

  1984cited by this paper
• An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.

  1979cited by this paper
• Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

  1978cited by this paper
• MIRD Pamphlet #11: S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs

  1975cited by this paper

• Radiolabeled Antibodies for Therapy of Brain Tumors

  2001cites this paper
• Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas

  1997cites this paper